GLB 002
Alternative Names: GLB-002Latest Information Update: 31 Jan 2024
At a glance
- Originator GluBio Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action IKZF1 protein modulators; IKZF3 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
- Preclinical Diffuse large B cell lymphoma; Multiple myeloma
Most Recent Events
- 11 Jan 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (PO) (NCT06219356)
- 15 Dec 2023 Preclinical trials in Diffuse large B cell lymphoma in USA (unspecified route), prior to December 2023 (GluBio Therapeutics pipeline, December 2023)
- 15 Dec 2023 Preclinical trials in Multiple myeloma in USA (unspecified route), prior to December 2023 (GluBio Therapeutics pipeline, December 2023)